MSDC-0602K

Product NameMSDC-0602K
CAS1314533-27-1
MFC19H18KNO5S
MW411.51
EINECS
MOL File1314533-27-1.mol

Chemical Properties

storage temp.	Store at -20°C
form	Solid
color	White to off-white

Usage And Synthesis

Uses

Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM[1]. Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance[2]. Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide[3].

in vivo

Diabetic db/db and MS-NASH mice are treated with Azemiglitazone potassium by oral gavage, Liraglutide by s.c. injection, or combination Azemiglitazone potassium + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis (NASH).

Animal Model:	Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice^[1]
Dosage:	30 mg/kg MSDC-0602K; 0.2 mg/kg Liraglutide (obtained from MedChemExpress; HY-P0014)
Administration:	MSDC-0602K gavage daily, Liraglutide s.c. injection every other day, or combined MSDC-0602K+ Liraglutide
Result:	MSDC-0602K corrected glycemia and reduced insulinemia when given alone, or in combination with Liraglutide. However, MSDC-0602K + Liraglutide combination more significantly improved glucose tolerance and liver histology.

IC 50

PPAR-γ: 18.25 μM (IC₅₀)

References

[1] Zhouji Chen, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. DOI:10.1074/jbc.M112.363960
[2] Jerry R Colca, et al. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs. 2018 Jul;27(7):631-636. DOI:10.1080/13543784.2018.1494153
[3] Dakota R Kamm, et al. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. J Biol Chem. Jan-Jun 2021;296:100807. DOI:10.1016/j.jbc.2021.100807

MSDC-0602K Supplier

MSDC-0602K manufacturers

Related Product Information

Send Inquriy